Medan, Indonesia – Chronic kidney disease (CKD) remains a global public health problem due to its increasing prevalence, poor outcomes, low treatment rate, and high costs. However, clinical pharmacy education (CPE) can improve outcomes and optimize health care costs.
A quasi-experimental economic evaluation comparing CPE impact on six-months mortality of JAMKESMAS-insured stage 4 and 5 CKD patients was conducted in Haji Adam Malik Hospital, Indonesia. The group of CKD patients that received care by health care providers that were given CPE on drug related problems (DRPs) and dose adjustment had lower cost-effectiveness (CE) ratios compared to those without CPE.
Active roles of clinical pharmacists in patient care in HAM Hospital, Medan, Indonesia, improve outcomes and reduce costs for the treatment of infection in CKD stage 4 and 5.
This study evaluated the impacts of clinical pharmacy education (CPE) on efficiency and effectiveness of infection management among patients with chronic kidney disease (CKD) stage 4 and 5 in Haji Adam Malik (HAM) Hospital, Indonesia.Â
Treatment of CKD stage 4 and 5 with CPE was more effective and cost-effective compared to those without CPE. There were more lives-saved (88.89%) in treatment of stage 4 CKD patients with CPE compared to those without CPE (78.57%). There were also more lives-saved (65.45%) in treatment of stage 5 CKD patients with CPE compared to those without CPE (57.58%).
Dr. Nasution, coauthor of this study, quoted “This study suggests that active contribution of pharmacists in the management of CKD patients improve efficiency and effectiveness.”
Value in Health Regional Issues (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.